北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤放疗科  > 期刊论文
学科主题: 临床医学
题名:
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial
作者: Li, Jin-luan; Ji, Jia-fu2; Cai, Yong1; Li, Xiao-fan; Li, Yong-heng; Wu, Hao; Xu, Bo; Dou, Fang-yuan3; Li, Zi-yu2; Bu, Zhao-de2; Wu, Ai-wen2; Tham, Ivan W. K.4
关键词: Intensity-modulated radiotherapy ; Capecitabine ; Rectal cancer
刊名: RADIOTHERAPY AND ONCOLOGY
发表日期: 2012
DOI: 10.1016/j.radonc.2011.07.030
卷: 102, 期:1, 页:4-9
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Radiology, Nuclear Medicine & Medical Imaging
研究领域[WOS]: Oncology ; Radiology, Nuclear Medicine & Medical Imaging
关键词[WOS]: TOTAL MESORECTAL EXCISION ; RADIATION-THERAPY ; SMALL-BOWEL ; CHEMORADIOTHERAPY ; SURVIVAL ; VOLUME ; RADIOCHEMOTHERAPY ; LYMPHADENECTOMY ; CHEMOTHERAPY ; NETHERLANDS
英文摘要:

Purpose: We aimed to assess the safety and efficacy of preoperative intensity-modulated radiotherapy (IMRT) with oral capecitabine in patients with locally advanced mid-low rectal cancer using a concomitant boost technique.

Materials and methods: Patients with resectable locally advanced mid-low rectal cancer (node-negative >= T3 or any node-positive tumor) were eligible. The eligible patients received IMRT to 2 dose levels simultaneously (50.6 and 41.8 Gy in 22 fractions) with concurrent capecitabine 825 mg/m(2) twice daily 5 days/week. The primary end point included toxicity, postoperative complication, and pathological complete response rate (ypCR). The secondary endpoints included local recurrence rate, progression-free survival (PFS), and overall survival (OS).

Results: Sixty-three eligible patients were enrolled; five patients did not undergo surgery. Of the 58 patients evaluable for pathologic response, the ypCR rate was 31.0%(95% CI 19.1-42.9). Grade 3 toxicities included diarrhea (9.5%), radiation dermatitis (3.2%), and neutropenia (1.6%). There was no Grade 4 toxicity reported. Four (6.9%) patients developed postoperative complications. Two-year local recurrence rate, PFS, and OS were 5.7%, 90.5%, and 96.0%, respectively.

Conclusions: The design of preoperative concurrent boost IMRT with oral capecitabine could achieve high rate of ypCR with an acceptable toxicity profile. (C) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 102 (2012) 4-9

语种: 英语
项目资助者: Beijing Cancer Hospital
WOS记录号: WOS:000300654700002
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66037
Appears in Collections:北京大学临床肿瘤学院_肿瘤放疗科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Dept Radiat Oncol, Sch Oncol, Canc Hosp,Beijing Canc Hosp & Inst, Beijing 100142, Peoples R China
2.Beijing Canc Hosp & Inst, Dept Surg Gastroenterol, Beijing, Peoples R China
3.Natl Univ Canc Inst, Dept Radiat Oncol, Singapore, Singapore
4.Beijing Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China

Recommended Citation:
Li, Jin-luan,Ji, Jia-fu,Cai, Yong,et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial[J]. RADIOTHERAPY AND ONCOLOGY,2012,102(1):4-9.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, Jin-luan]'s Articles
[Ji, Jia-fu]'s Articles
[Cai, Yong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, Jin-luan]‘s Articles
[Ji, Jia-fu]‘s Articles
[Cai, Yong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace